Gazelle Parent, Inc. (OBX)

Gazelle Parent, Inc. exists as a purpose-built merger vehicle. The company itself is essentially a shell—created in 2024 to facilitate the combination of two cancer-focused biotech companies into a single operating entity. On closing, expected in the third quarter of 2026, Gazelle will be renamed Obsidian Therapeutics, Inc., with shares trading on Nasdaq under the ticker OBX.

The merger brings together Obsidian Therapeutics, a private cell therapy developer, and Galera Therapeutics (GRTX), a publicly traded small-molecule biotech company. Obsidian’s main program, OBX-115, is an engineered tumor-infiltrating lymphocyte (TIL) cell therapy—a form of adoptive cell therapy where immune cells extracted from a patient’s own tumor are expanded and enhanced in the laboratory, then infused back to attack cancer.

The Two Operating Platforms

Obsidian’s lead asset, OBX-115, is in Phase 2 testing for melanoma that has resisted checkpoint inhibitor therapy (anti-PD-1 drugs), as well as Phase 1 work in non-small cell lung cancer. Early data showed a 50% objective response rate in melanoma with a complete response rate of 25%, achieved without the high-dose interleukin-2 (IL-2) that traditional TIL therapies require. The therapy uses a membrane-bound IL-15 enhancement to boost cell persistence and activity. OBX-115 has earned FDA Fast Track and Regenerative Medicine Advanced Therapy designations.

Galera, meanwhile, develops small-molecule drugs targeting radiation-induced side effects and difficult cancers. Its lead candidate is avasopasem manganese, a dismutase mimetic for severe oral mucositis from head-and-neck cancer radiotherapy, along with a secondary indication in radiation-induced esophagitis. Galera also has tilarginine in early clinical development for triple-negative breast cancer.

Capital and Ownership

The merger drew an oversubscribed $350 million private placement from new investors. Upon closing, pre-merger Obsidian holders are expected to own roughly 53% of the combined company, pre-merger Galera shareholders about 2%, and the new investors about 45%. This ownership structure reflects Obsidian’s larger valuation and the fresh capital infusion tied to the transaction.

What to Watch

The merged entity’s value will hinge almost entirely on OBX-115’s path through Phase 2—interim data were to be presented at the 2026 ASCO meeting. Cell therapies can command substantial premiums if clinical results are strong, but manufacturing complexity and higher cost per treatment (relative to small molecules) create execution risk. Galera’s small-molecule programs provide some diversification but remain earlier stage. The combined entity inherits Galera’s public reporting obligations and will be subject to the typical scrutiny of a Nasdaq biotech: quarterly filings, regulatory updates, clinical readouts, and equity raises if cash burns faster than anticipated.

As a shell company in transition, Gazelle Parent carries no meaningful operations or revenue. Its worth is purely the sum of the two operating companies it will house. Reading the 10-K and merger proxy will show the detailed financial position of both predecessors; clinical trial sites and patient enrollment numbers are often disclosed in SEC filings and company press releases.